Studies on Siglecs expressed on B lymphocytes and their glycan ligands

2017 Fiscal Year Final Research Report

• Project/Area Number: 26293062
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: General medical chemistry
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: TSUBATA Takeshi 東京医科歯科大学, 難治疾患研究所, 教授 (80197756)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: シグレック / CD22 / Siglec-10 シスリガンド / CD45 / シアル酸 / シグナル伝達 / ギラン・バレー症候群

Outline of Final Research Achievements

Siglecs expressed in various immune cells recognize sialic acids and mostly inhibit cell activation. In this study, we demonstrated that sialic acid-containing Siglec ligands expressed on the same cell (cis-ligands) can be efficiently labeled by proximity labeling. We elucidated how cis-ligands regulate Siglecs by analyzing CD45 that was isolated as a cis-ligand of CD22, a Siglec. Moreover, we demonstrated that the polymorphism of Siglec-10 associated with Guillain-Barre syndrome in which autoantibodies to gangliosides, sialic acid-containing glycolipids, are produced regulates binding of Siglec-10 to gangliosides. This result suggests that decreased activity of Siglec-10 allows immune responses to gangliosides, resulting in development of this syndrome.

Free Research Field

生化学、免疫学